- Home
- COEP vs VRCA Comparison
COEP vs VRCA Comparison
Compare COEP & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COEP | VRCA |
|---|---|---|
| Founded | 2017 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 32.7M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | COEP | VRCA |
|---|---|---|
| Price | $16.67 | $8.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 69.6K | ★ 359.1K |
| Earning Date | 11-14-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $500,996.00 | ★ $30,829,000.00 |
| Revenue This Year | N/A | $332.45 |
| Revenue Next Year | N/A | $12.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 234.73 |
| 52 Week Low | $2.31 | $3.28 |
| 52 Week High | $21.41 | $12.50 |
Technical Indicators
Market Signals| Indicator | COEP | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | 52.18 | 70.38 |
| Support Level | $15.40 | $6.26 |
| Resistance Level | $21.41 | $9.82 |
| Average True Range (ATR) | 1.57 | 0.90 |
| MACD | -0.04 | 0.42 |
| Stochastic Oscillator | 34.26 | 77.65 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.